NovaBridge Biosciences ADR (NBP)
NASDAQ: NBPHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NBP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $158.92M
- EPS (TTM)
- -$0.67
- Dividend yield
- None
- 52-week range
- 1.31 – 6.79
- Day range
- 1.37 – 1.41
- Volume / Avg
- 353.90K / 387.52K
- Beta
- —
- Shares outstanding
- 116.00M
52-week range
NBP stock today
NovaBridge Biosciences (NBP) closed at $1.37 on Oct 7, down 2.14% (-$0.03), versus the S&P 500's 0.22% decline. At this level, NBP sits near the bottom of its 52-week range of $1.31 to $6.79: 79.8% below the high, set on Oct 16, 2025 and 4.6% above the low. NBP is down 65.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 68.6%.
NovaBridge Biosciences has posted a net loss over the last twelve months (EPS of -$0.67), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NovaBridge Biosciences
Company profileNovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Srishti Gupta M.D.
- Headquarters
- Rockville, MD
- Employees
- 30
- IPO year
- 2020
- Website
- novabridge.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$9.00+556.93%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
NovaBridge Biosciences peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MSLESatellos Bioscience Inc. | 7.63 | +1.19% | $161.88M | vs NBP |
| NKTXNkarta Inc. | 2.27 | -1.73% | $162.59M | vs NBP |
| CUECue Biopharma Inc. | 22.51 | -2.72% | $163.52M | vs NBP |
| MDWDMediWound Ltd. | 12.85 | -2.28% | $165.90M | vs NBP |
| PEPGPepGen Inc. | 2.40 | +3.90% | $166.01M | vs NBP |
| MENSJyong Biotech Ltd. | 2.06 | +1.98% | $156.62M | vs NBP |
| ALXOALX Oncology Holdings Inc. | 1.13 | +1.80% | $156.25M | vs NBP |
| NERVMinerva Neurosciences Inc | 3.27 | -4.66% | $156.13M | vs NBP |
Indexes, lists and sector
Appears in lists
NovaBridge Biosciences stock FAQ
What is NovaBridge Biosciences's stock price today?
NBP last traded at $1.37 as of Oct 7, 4:00 PM EDT, down 2.14% on the day. Prices are delayed at least 15 minutes.
Who is NovaBridge Biosciences's CEO?
Dr. Srishti Gupta M.D. is the chief executive officer of NovaBridge Biosciences ADR, which has about 30 employees.
What is the NBP 52-week high?
The 52-week high for NBP is $6.79 and the 52-week low is $1.31. The stock is currently 79.8% below its high.